These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23639270)

  • 1. Recent-onset atrial fibrillation in patients with left ventricular dysfunction: amiodarone or vernakalant?
    Conde D; Costabel JP; Alves de Lima A
    Can J Cardiol; 2013 Oct; 29(10):1330.e11-1330.e12. PubMed ID: 23639270
    [No Abstract]   [Full Text] [Related]  

  • 2. Conversion of recent onset atrial fibrillation: which drug is faster?
    Conde D
    Am J Emerg Med; 2013 Sep; 31(9):1410-1. PubMed ID: 23796978
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
    Hirt MN; Eschenhagen T
    Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vernakalant hydrochloride to treat atrial fibrillation.
    Brown RA; Lau YC; Lip GY
    Expert Opin Pharmacother; 2014 Apr; 15(6):865-72. PubMed ID: 24617913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vernakalant in the management of atrial fibrillation.
    Cheng JW
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
    Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The AVRO study].
    Capucci A; Di Pasquale G
    G Ital Cardiol (Rome); 2011 Nov; 12(11):693-6. PubMed ID: 22048443
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I; Graydon R; Camm AJ
    Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.
    Vizzardi E; Salghetti F; Bonadei I; Gelsomino S; Lorusso R; D'Aloia A; Curnis A
    Cardiovasc Ther; 2013 Oct; 31(5):e55-62. PubMed ID: 23398692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vernakalant. Too dangerous in atrial fibrillation.
    Prescrire Int; 2012 May; 21(127):119-22. PubMed ID: 22827000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of intravenous vernakalant for atrial fibrillation conversion in the regular ward under only bedside monitoring.
    Manolis AS; Bethanis S; Metaxa S; Polytarchou K; Sakellaris N; Pyrros I
    Hellenic J Cardiol; 2019; 60(1):54-56. PubMed ID: 29454598
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
    Guerra F; Matassini MV; Scappini L; Urbinati A; Capucci A
    Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1067-75. PubMed ID: 25096598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG; Roos JS; Kavanagh KM; Dickinson G
    Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New anthyarrhythmic drugs for atrial fibrillation.
    Matassini MV; Guerra F; Scappini L; Urbinati A; Capucci A
    Future Cardiol; 2015; 11(6):705-17. PubMed ID: 26631497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y; Dobrev D
    Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vernakalant: pharmacology electrophysiology, safety and efficacy.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
    Drugs Today (Barc); 2008 May; 44(5):325-9. PubMed ID: 18548135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D
    Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.